In the current study we have demonstrated a similar phenomenon for the A549 lung carcinoma cell line (expressing wild-type p53) and the MDA–MB-231 breast carcinoma cell line (expressing mutant p53) after treatment with clinically relevant concentrations of cisplatin (≤10 μM). This evidence concerns the gene TP53 and breast carcinoma.